Artemis Investment Management LLP Sells 135,994 Shares of Natera, Inc. (NASDAQ:NTRA)

Artemis Investment Management LLP lowered its position in shares of Natera, Inc. (NASDAQ:NTRA) by 51.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 129,027 shares of the medical research company’s stock after selling 135,994 shares during the period. Artemis Investment Management LLP owned about 0.10% of Natera worth $20,425,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc boosted its position in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the period. Itau Unibanco Holding S.A. bought a new stake in shares of Natera in the 2nd quarter valued at about $28,000. Quarry LP increased its stake in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after buying an additional 190 shares during the period. Covestor Ltd lifted its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the period. Finally, GAMMA Investing LLC increased its position in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on NTRA shares. Robert W. Baird lifted their target price on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Craig Hallum boosted their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Canaccord Genuity Group boosted their price target on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Finally, Sanford C. Bernstein increased their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $160.63.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 1,196 shares of the stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $118.21, for a total transaction of $141,379.16. Following the sale, the insider now owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This represents a 1.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roelof Botha sold 87,473 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $169.12, for a total value of $14,793,433.76. Following the completion of the transaction, the director now owns 1,224,787 shares of the company’s stock, valued at approximately $207,135,977.44. This represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 123,409 shares of company stock valued at $20,045,631 over the last three months. 7.60% of the stock is currently owned by insiders.

Natera Trading Down 6.0 %

NASDAQ:NTRA opened at $158.36 on Friday. Natera, Inc. has a 12 month low of $62.96 and a 12 month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $164.00 and its 200 day moving average is $134.28. The stock has a market capitalization of $20.91 billion, a PE ratio of -89.98 and a beta of 1.65.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.95) earnings per share. Sell-side analysts expect that Natera, Inc. will post -1.61 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.